“…LL7 is a randomized prospective phase IIb study, including three co-primary end-points, such as PFS, time to treatment failure (TTF), and OS. The results of the study have shown a significant superiority of afatinib over gefitinib both in PFS (11 vs 10,9 months; HR: 0.74, 95%CI: 0.57-0.95, p: 0.017) and TTF (13.7 vs 11.5 months; HR: 0.73, 95%CI: 0.58-0.92, p: 0.007), regardless from the specific type of EGFR activating mutation (Del19 vs L858R) (Park et al, 2016a). A significant increment of RR has been also reported with afatinib (73% vs 56%, p: 0.002).…”